- •Table of Contents
- •Case Studies
- •Volume 2 Stephen m. Stahl
- •Thomas l. Schwartz
- •It furthers the University’s mission by disseminating knowledge in the pursuit of education, learning and research at the highest international levels of excellence.
- •Information on this title: www.Cambridge.Org/9781107607330
- •Illness – Chemotherapy – Examinations, questions, etc. |
- •Isbn 978-1-107-60733-0 Paperback
- •Introduction
- •Learning objectives
- •Accreditation and credit designation statements
- •Optional posttest and cme credit instructions (see p. 441) Peer review
- •Disclosures
- •Authors/developers
- •Disclosure of off-label use
- •Disclaimer
- •Cultural and linguistic competency
- •Provider
- •Support
- •Patient evaluation on intake
- •Psychiatric history
- •Psychotherapy history
- •Patient evaluation on initial visit
- •Current medications
- •Question
- •Attending physician’s mental notes: initial evaluation
- •Question
- •Attending physician’s mental notes: initial evaluation (continued)
- •Further investigation
- •Case outcome: first interim follow-up visit four weeks later
- •Question
- •Case outcome: second interim follow-up visit at two months
- •Attending physician’s mental notes: interim follow-up visit at three months
- •Question
- •Attending physician’s mental notes: second interim follow-up visit at three months
- •Case outcome: interim follow-up visits through six months
- •Question
- •Attending physician’s mental notes: interim follow-up visits through 12 months
- •Case outcome: interim follow-up visits through 24 months
- •Case debrief
- •Take-home points
- •Performance in practice: confessions of a psychopharmacologist
- •Tips and pearls
- •Psychotherapy moment
- •Psychopharmacology components
- •Psychotherapy
- •Documentation
- •Patient evaluation on intake
- •Psychiatric history
- •Attending physician’s mental notes: initial evaluation
- •Further investigation
- •Question
- •Attending physician’s mental notes: initial evaluation (continued)
- •Case outcome: interim follow-ups through six months
- •Question
- •Attending physician’s mental notes: nine months
- •Case outcome: interim follow-ups through nine months
- •Question
- •Attending physician’s mental notes: nine-month follow-ups
- •Question
- •Attending physician’s mental notes: interim follow-up through nine months (continued)
- •Case outcome and multiple interim follow-ups to 24 months
- •Case debrief
- •Take-home points
- •Performance in practice: confessions of a psychopharmacologist
- •Tips and pearls
- •Tardive dyskinesia
- •Tardive dyskinesia facts
- •Tardive dyskinesia treatments
- •Pretest self-assessment question (answer at the end of the case)
- •Patient evaluation on intake
- •Psychiatric history
- •Attending physician’s mental notes: initial evaluation
- •Further investigation
- •Question
- •Attending physician’s mental notes: initial evaluation (continued)
- •Case outcome: interim follow-ups through four months
- •Question
- •Attending physician’s mental notes: nine months
- •Case outcome: interim follow-ups through nine months
- •Question
- •Attending physician’s mental notes: 9–12 month follow-ups
- •Question
- •Case outcome: interim follow-ups through 12 months
- •Case outcome: multiple interim follow-ups through 16 months
- •Attending physician’s mental notes: 16-month follow-ups
- •Case debrief
- •Take-home points
- •Performance in practice: confessions of a psychopharmacologist
- •Tips and pearls
- •Abnormal Involuntary Movement Scale (aims)
- •Aims instructions
- •Case outcome: use of outcome measures
- •Posttest self-assessment question and answer
- •Patient evaluation on intake
- •Psychiatric history
- •Attending physician’s mental notes: initial evaluation
- •Attending physician’s mental notes: initial evaluation (continued)
- •Further investigation
- •Question
- •Case outcome: interim follow-ups through three months
- •Question
- •Attending physician’s mental notes: four months
- •Question
- •Case outcome: interim follow-ups through six months
- •Attending physician’s mental notes: interim follow-up, nine months (continued)
- •Case outcome and multiple interim follow-ups to 12–120 months
- •Case debrief
- •Take-home points
- •Performance in practice: confessions of a psychopharmacologist
- •Tips and pearls
- •Mechanism of action moment How does vns theoretically work?
- •Vns side effects
- •Neurostimulation and neuromodulatory devices other than vns
- •Patient evaluation on intake
- •Psychiatric history
- •Attending physician’s mental notes: initial evaluation
- •Further investigation
- •Question
- •Attending physician’s mental notes: initial evaluation (continued)
- •Case outcome: interim follow-ups through one month
- •Question
- •Case outcome: interim follow-ups through two months
- •Case outcome: interim follow-ups through three months
- •Question
- •Attending physician’s mental notes: four-month follow-ups
- •Question
- •Case outcome: interim follow-ups through four months (continued)
- •Attending physician’s mental notes: interim follow-ups through four months
- •Case outcome and multiple interim follow-ups to six months
- •Case debrief
- •Take-home points
- •Performance in practice: confessions of a psychopharmacologist
- •Tips and pearls
- •Is quetiapine (Seroquel) an antipsychotic, anti-manic, antidepressant, anxiolytic, or a hypnotic?
- •Pharmacodynamics of quetiapine and norquetiapine
- •Pretest self-assessment question (answer at the end of the case)
- •Patient evaluation on intake
- •Psychiatric history
- •Attending physician’s mental notes: initial evaluation
- •Further investigation
- •Attending physician’s mental notes: initial evaluation (continued)
- •Case outcome: interim follow-ups through one month
- •Case outcome: interim follow-ups through two months
- •Attending physician’s mental notes: two months
- •Question
- •Case outcome: interim follow-ups through two months
- •Case outcome: interim follow-ups through three months
- •Question
- •Case outcome and multiple interim follow-ups up to six months
- •Case debrief
- •Take-home points
- •Performance in practice: confessions of a psychopharmacologist
- •Pharmacodynamic moment
- •What is worse in causing escalated mania or mixed features, antidepressants or stimulants?
- •Should unipolar antidepressants be used in bipolar disorder?
- •Does clonazepam (Klonopin) work in bipolar mania?
- •Posttest self-assessment question and answer
- •Patient evaluation on intake
- •Psychiatric history
- •Question
- •Case outcome
- •Case debrief
- •Take-home points
- •Tips and pearls
- •Patient evaluation on intake
- •Psychiatric history
- •Attending physician’s mental notes: initial evaluation
- •Further investigation
- •Question
- •Attending physician’s mental notes: initial evaluation (continued)
- •Case outcome: interim follow-ups through three months
- •Question
- •Attending physician’s mental notes: four months
- •Case outcome: interim follow-ups through six months
- •Case outcome: interim follow-ups through nine months
- •Question
- •Attending physician’s mental notes: nine-month follow-ups
- •Attending physician’s mental notes: interim follow-up, nine months (continued)
- •Case outcome and multiple interim follow-ups to 24 months
- •Case debrief
- •Take-home points
- •Performance in practice: confessions of a psychopharmacologist
- •Tips and pearls
- •Treating aawg with metformin
- •Posttest self-assessment question and answer
- •Patient evaluation on intake
- •Psychiatric history
- •Attending physician’s mental notes: initial evaluation
- •Further investigation
- •Question
- •Attending physician’s mental notes: initial evaluation (continued)
- •Case outcome: interim follow-ups through six months
- •Attending physician’s mental notes: six months
- •Case outcome: interim follow-ups through nine months
- •Case outcome: interim follow-ups through 18 months
- •Attending physician’s mental notes: through 20 months
- •Question
- •Case outcome: interim follow-ups through 24 months
- •Question
- •Attending physician’s mental notes: 24-month follow-ups
- •Case outcome: interim follow-up, 36 months
- •Attending physician’s mental notes: 48-month follow-ups
- •Question
- •Case outcome and multiple interim follow-ups to 48 months
- •Case debrief
- •Take-home points
- •Performance in practice: confessions of a psychopharmacologist
- •Tips and pearls
- •Techniques for switching antipsychotics
- •Pretest self-assessment question (answer at the end of the case)
- •Patient evaluation on intake
- •Psychiatric history
- •Question
- •Case outcome
- •Case debrief
- •Clozapine sialorrhea statistics and etiology
- •Possible antidotes for cis
- •Posttest self-assessment question and answer
- •Patient evaluation on intake
- •Psychiatric history
- •Further investigation
- •Question
- •Attending physician’s mental notes: initial evaluation (continued)
- •Case outcome: interim follow-ups through three months
- •Attending physician’s mental notes: six months
- •Case outcome: interim follow-ups through nine months
- •Case outcome: interim follow-ups through 12 months
- •Case outcome: interim follow-ups through 12 months (continued)
- •Question
- •Attending physician’s mental notes: 12 month follow-ups
- •Case outcome: interim follow-up, 24 months
- •Attending physician’s mental notes: 36-month follow-ups
- •Case outcome and multiple interim follow-ups to 60 months
- •Case debrief
- •Take-home points
- •Performance in practice: confessions of a psychopharmacologist
- •Tips and pearls
- •A pharmacodynamic moment
- •Antihistamine and the sleep–wake switch
- •Serotonin receptor antagonism and sleep
- •What about 5-ht1d receptor antagonism?
- •What about 5-ht7 receptor antagonism?
- •Patient evaluation on intake
- •Psychiatric history
- •Current medications
- •Question
- •Attending physician’s mental notes: initial evaluation
- •Question
- •Attending physician’s mental notes: initial evaluation (continued)
- •Further investigation
- •Case outcome: first interim follow-up visit four weeks later
- •Question
- •Case outcome: second interim follow-up visit at two months
- •Attending physician’s mental notes: second interim follow-up visit at two months
- •Question
- •Case outcome: interim follow-up visits through seven months
- •Question
- •Attending physician’s mental notes: interim follow-up visits through seven months
- •Case outcome: interim follow-up visits through 24 months
- •Case debrief
- •Take-home points
- •Performance in practice: confessions of a psychopharmacologist
- •Tips and pearls
- •Mechanism of action moment
- •Patient evaluation on intake
- •Psychiatric history
- •Psychotherapy history
- •Patient evaluation on initial visit
- •Current medications
- •Question
- •Attending physician’s mental notes: initial evaluation
- •Question
- •Attending physician’s mental notes: initial evaluation (continued)
- •Further investigation
- •Case outcome: first interim follow-up visit eight weeks later
- •Question
- •Case outcome: second and third interim follow-up visits at three months
- •Attending physician’s mental notes: second interim follow-up visit at three months
- •Question
- •Attending physician’s mental notes: second interim follow-up visit at three months (continued)
- •Case outcome: interim follow-up visits through five months
- •Question
- •Attending physician’s mental notes: interim follow-up visits through nine months
- •Case outcome: interim follow-up visits through 12 months
- •Attending physician mental notes
- •Case outcome: interim follow-up visits through 15 months
- •Question
- •Case debrief
- •Take-home points
- •Performance in practice: confessions of a psychopharmacologist
- •Tips and pearls
- •Pharmacoeconomic and regulatory moment
- •How many ways can a drug be turned into a slow-release preparation?
- •Pretest self-assessment question (answer at the end of the case)
- •Patient evaluation on intake
- •Psychiatric history
- •Medication history
- •Psychotherapy history
- •Social and personal history
- •Medical history
- •Family history
- •Patient evaluation on initial visit
- •Current medications
- •Question
- •Attending physician’s mental notes: initial evaluation
- •Question
- •Attending physician’s mental notes: initial evaluation (continued)
- •Further investigation
- •Case outcome: first interim follow-up visit four to six weeks later
- •Question
- •Attending physician’s mental notes: interim follow-up visits through three months
- •Case outcome: interim follow-up visits through three months
- •Question
- •Attending physician’s mental notes: interim follow-up visits through three months (continued)
- •Case outcome: interim follow-up visits through six months
- •Attending physician’s mental notes: interim follow-up visits through six months
- •Case debrief
- •Take-home points
- •Performance in practice: confessions of a psychopharmacologist
- •Tips and pearls
- •Overview
- •Classification
- •Clinical manifestations
- •Therapy and management
- •Posttest self-assessment question and answer
- •Pretest self-assessment question (answer at the end of the case)
- •Patient evaluation on intake
- •Psychiatric history
- •Current medications
- •Question
- •Attending physician’s mental notes: initial evaluation
- •Question
- •Attending physician’s mental notes: initial evaluation (continued)
- •Further investigation
- •Case outcome: first interim follow-up visit six weeks later
- •Question
- •Attending physician’s mental notes: interim follow-up visits through six months
- •Case outcome: interim follow-up visits through six months
- •Question
- •Attending physician’s mental notes: interim follow-up visit through six months (continued)
- •Case outcome: interim follow-up visits through nine months
- •Question
- •Attending physician’s mental notes: interim follow-up visits through nine months
- •Case outcome: interim follow-up visits through 15 months
- •Case debrief
- •Take-home points
- •Performance in practice: confessions of a psychopharmacologist
- •Tips and pearls
- •Neurocircuitry moment
- •Treatments for ocd
- •Posttest-self assessment question and answer
- •Patient evaluation on intake
- •Psychiatric history
- •Social and personal history
- •Patient evaluation on initial visit
- •Current medications
- •Question
- •Attending physician’s mental notes: initial evaluation
- •Question
- •Attending physician’s mental notes: initial evaluation (continued)
- •Further investigation
- •Case outcome: first interim follow-up visit four weeks later
- •Question
- •Attending physician’s mental notes: second interim follow-up visit at two months
- •Case outcome: second interim follow-up visit at two months
- •Question
- •Attending physician’s mental notes: second interim follow-up visit at two months (continued)
- •Case outcome: interim follow-up visits through four months
- •Question
- •Attending physician’s mental notes: interim follow-up visits through four months
- •Case outcome: interim follow-up visits through nine months
- •Attending physician’s mental notes: interim follow-up visits through 12 months
- •Case outcome: interim follow-up visits through 18 months
- •Case debrief
- •Take-home points
- •Performance in practice: confessions of a psychopharmacologist
- •Tips and pearls
- •Mechanism of action moment
- •Diagnosis
- •Etiology
- •Rls and comorbidity
- •Rls treatment
- •Posttest self-assessment question and answer
- •Patient evaluation on intake
- •Psychiatric history
- •Current medications
- •Question
- •Attending physician’s mental notes: initial evaluation
- •Question
- •Attending physician’s mental notes: initial evaluation (continued)
- •Further investigation
- •Case outcome: first interim follow-up visit four weeks later
- •Question
- •Attending physician’s mental notes: second interim follow-up visit at two months
- •Case outcome: second interim follow-up visit at two months
- •Question
- •Attending physician’s mental notes: second interim follow-up visit at two months (continued)
- •Case outcome: interim follow-up visits at three months
- •Question
- •Case outcome: interim follow-up visit at four months
- •Attending physician’s mental notes: interim follow-up visits through four months
- •Case outcome: interim follow-up visits through six months
- •Case debrief
- •Take-home points
- •Performance in practice: confessions of a psychopharmacologist
- •Tips and pearls
- •Pharmacokinetic moment
- •Patient evaluation on intake
- •Psychiatric history
- •Psychotherapy history
- •Patient evaluation on initial visit
- •Current medications
- •Question
- •Attending physician’s mental notes: initial evaluation
- •Question
- •Attending physician’s mental notes: initial evaluation (continued)
- •Further investigation
- •Case outcome: first interim follow-up visit four weeks later
- •Question
- •Attending physician’s mental notes: second interim follow-up visit at three months
- •Case outcome: second interim follow-up visit at three months
- •Question
- •Attending physician’s mental notes: second interim follow-up visit at three months (continued)
- •Case outcome: interim follow-up visits through 12 months
- •Question
- •Attending physician’s mental notes: interim follow-up visits through 24 months
- •Case debrief
- •Take-home points
- •Performance in practice: confessions of a psychopharmacologist
- •Tips and pearls
- •Patient evaluation on intake
- •Psychiatric history
- •Current medications
- •Question
- •Attending physician’s mental notes: initial evaluation
- •Question
- •Attending physician’s mental notes: initial evaluation (continued)
- •Further investigation
- •Case outcome: first interim follow-up visit three months later
- •Question
- •Case outcome: first interim follow-up visit three months later (continued)
- •Question
- •Attending physician’s mental notes: second interim follow-up visit at six months
- •Case outcome: second interim follow-up visit at six months
- •Question
- •Case outcome: interim follow-up visits through nine months
- •Question
- •Attending physician’s mental notes: interim follow-up visits through nine months
- •Case outcome: interim follow-up visits through 36 months
- •Question
- •Case outcome: interim follow-up visits through 48 months
- •Case debrief
- •Take-home points
- •Performance in practice: confessions of a psychopharmacologist
- •Tips and pearls
- •Patient evaluation on intake
- •Psychiatric history
- •Patient evaluation on initial visit
- •Current medications
- •Question
- •Attending physician’s mental notes: initial evaluation
- •Question
- •Attending physician’s mental notes: initial evaluation (continued)
- •Further investigation
- •Case outcome: first interim follow-up visits four and eight weeks later
- •Question
- •Attending physician’s mental notes: second interim follow-up visit at three months
- •Case outcome: second interim follow-up visit at three months
- •Question
- •Attending physician’s mental notes: second interim follow-up visit at three months (continued)
- •Case outcome: interim follow-up visits through six months
- •Question
- •Attending physician’s mental notes: interim follow-up visits through six months
- •Case outcome: interim follow-up visits through nine months
- •Attending physician’s mental notes: interim follow-up visits through nine months
- •Question
- •Case outcome: interim follow-up visits through 15 months
- •Case debrief
- •Take-home points
- •Performance in practice: confessions of a psychopharmacologist
- •Tips and pearls
- •Neuropsychiatric moment
- •Causes, incidence, and risk factors
- •Symptoms
- •Signs and tests
- •Treatment
- •Prognosis
- •Pharmacodynamic moment
- •Patient evaluation on intake
- •Psychiatric history
- •Psychotherapy history
- •Patient evaluation on initial visit
- •Current medications
- •Question
- •Attending physician’s mental notes: initial evaluation
- •Question
- •Attending physician’s mental notes: initial evaluation (continued)
- •Further investigation
- •Case outcome: first interim follow-up visit four weeks later
- •Question
- •Attending physician’s mental notes: second interim follow-up visit at two months
- •Case outcome: second interim follow-up visit at two months
- •Question
- •Case outcome: interim follow-up visits through five years
- •Question
- •Attending physician’s mental notes: interim follow-up visits through five years
- •Case outcome: interim follow-up visits through six years
- •Question
- •Attending physician’s mental notes: interim visits through year six
- •Case outcome: interim follow-up visits through six years (continued)
- •Question
- •Attending physician’s mental notes: interim visits through year six (continued)
- •Case debrief
- •Take-home points
- •Performance in practice: confessions of a psychopharmacologist
- •Tips and pearls
- •Mechanism of action moment
- •Patient evaluation on intake
- •Psychiatric history
- •Psychotherapy history
- •Patient evaluation on initial visit
- •Current medications
- •Question
- •Attending physician’s mental notes: initial evaluation
- •Question
- •Attending physician’s mental notes: initial evaluation (continued)
- •Further investigation
- •Case outcome: first interim follow-up visits one to two weeks later
- •Question
- •Attending physician’s mental notes: second interim follow-up visit at three to four weeks
- •Case outcome: second interim follow-up visit at three to four weeks
- •Question
- •Case outcome: interim follow-up visits through four to six weeks later
- •Question
- •Attending physician’s mental notes: interim follow-up visits through six weeks
- •Case outcome interim follow-up visits through 10 weeks
- •Case debrief
- •Take-home points
- •Performance in practice: confessions of a psychopharmacologist
- •Tips and pearls
- •Chronic risks
- •Acute risks predictive of future suicide attempt include*
- •Summary
- •Posttest self-assessment question and answer
- •Patient evaluation on intake
- •Psychiatric history
- •Psychotherapy history
- •Patient evaluation on initial visit
- •Further investigation
- •Case outcome: first interim follow-up visits through six months
- •Question
- •Case outcome: second interim follow-up visits through 12 months
- •Question
- •Case outcome: second interim follow-up visits through 12 months (continued)
- •Question
- •Attending physician’s mental notes: interim visits through 18 months
- •Case outcome: interim follow-up visits through 18 months
- •Question
- •Case outcome: interim follow-up visits through 24 months
- •Question
- •Attending physician’s mental notes: interim follow-up visits through 24 months
- •Case outcome: interim follow-up visits through 24 months (continued)
- •Case debrief
- •Take-home points
- •Performance in practice: confessions of a psychopharmacologist
- •Tips and pearls
- •Gaba-a receptors and the positive allosteric modulation of the bZs
- •Gaba-a receptors: desensitization, tachyphylaxis, and tolerance
- •Why does this happen?
- •Patient evaluation on intake
- •Psychiatric history
- •Attending physician’s mental notes: initial evaluation
- •Question
- •Attending physician’s mental notes: initial evaluation (continued)
- •Further investigation
- •Case outcome: first interim follow-up visits through three months
- •Question
- •Case outcome: interim follow-up visits through four months
- •Question
- •Case outcome: interim follow-up visits through six months
- •Question
- •Attending physician’s mental notes: visits through six months
- •Case outcome: interim follow-up visits through nine months
- •Question
- •Case outcome: interim follow-up visits through nine months (continued)
- •Case debrief
- •Take-home points
- •Performance in practice: confessions of a psychopharmacologist
- •Tips and pearls
- •Pretest self-assessment question (answer at the end of the case)
- •Patient evaluation on intake
- •Psychiatric history
- •Case outcome: via telephone
- •Further investigation
- •Case outcome: first interim follow-up six hours later
- •Question
- •Attending physician’s mental notes: six hours later
- •Question
- •Attending physician’s mental notes: interim follow-up information through 72 hours
- •Case outcome: interim follow-up information through 72 hours
- •Case outcome: interim follow-up visits through 80 hours
- •Attending physician’s mental notes: interim follow-up information through 72 hours (continued)
- •Question
- •Case outcome: interim follow-up information through 92 hours
- •Case debrief
- •Take-home points
- •Performance in practice: confessions of a psychopharmacologist
- •Tips and pearls
- •Delirium primer
- •Posttest self-assessment question and answer
- •Pretest self-assessment question (answer at the end of the case)
- •Patient evaluation on intake
- •Psychiatric history
- •Psychotherapy history
- •Patient evaluation on initial visit
- •Current psychiatric medications
- •Question
- •Attending physician’s mental notes: initial evaluation
- •Question
- •Attending physician’s mental notes: initial evaluation (continued)
- •Case outcome: initial visit
- •Further investigation
- •Question
- •Case outcome: first interim follow-up visit one week later
- •Case debrief
- •Take-home points
- •Performance in practice: confessions of a psychopharmacologist
- •Tips and pearls
- •Mechanism of action moment
- •Disulfiram (Antabuse)
- •Naltrexone (ReVia)
- •Acamprosate (Campral)
- •Posttest self-assessment question and answer
- •Patient evaluation on intake
- •Psychiatric history
- •Social and personal history
- •Medical history
- •Family history
- •Medication history
- •Psychotherapy history
- •Patient evaluation on initial visit
- •Current psychiatric medications
- •Question
- •Attending physician’s mental notes: initial evaluation
- •Question
- •Attending physician’s mental notes: initial evaluation (continued)
- •Case outcome: initial visit
- •Further investigation
- •Case outcome: first interim follow-up visit two months later
- •Question
- •Case outcome: interim follow-up visits three to six months later
- •Attending physician’s mental notes: follow-up visit, six months
- •Case outcome: interim follow-up visits eight to 12 months later
- •Case debrief
- •Take-home points
- •Performance in practice: confessions of a psychopharmacologist
- •Tips and pearls
- •Medication management of adhd in children versus adults
- •Posttest self-assessment question and answer
- •Patient evaluation on intake
- •Psychiatric history
- •Patient evaluation on initial visit
- •Question
- •Attending physician’s mental notes: initial evaluation
- •Case outcome: initial visit
- •Question
- •Attending physician’s mental notes: initial evaluation (continued)
- •Case outcome: interim visit at six weeks
- •Case debrief
- •Take-home points
- •Patient’s genetic summary
- •Case outcome: initial visit
- •Question
- •Attending physician’s mental notes: initial evaluation (continued)
- •Case outcome: interim visit at four weeks
- •Case debrief
- •Take-home points
- •A short tutorial on the scientific background of this case
- •Patient’s genetic summary
- •Case outcome: initial visit
- •Question
- •Attending physician’s mental notes: initial evaluation (continued)
- •Case outcome: interim visit through 16 weeks
- •Case debrief
- •Take-home points
- •Cme online posttest and certificate instructions
- •Index of drug names
- •Index of case studies
Cme online posttest and certificate instructions
The estimated time for completion of this activity is 55.0 hours. There is a fee for the optional posttest, waived for NEI members.
1. Read the book in sequence, evaluating the content presented
2. Complete the posttest and activity evaluation, available only online at www.neiglobal.com/CME (under “Book”)
3. Print your certificate (if a score of 70% or more is achieved)
4. Questions? Call 888-535-5600, or email CustomerService@NEIglobal.com
Index of drug names
Abilify. See aripiprazole
acamprosate, 304, 394
Adderall-XR. See mixed amphetamine salts
Advair Diskus, 34
albuterol, 34, 148
Allegra. See fexofenadine
allopurinol, 34
Aloprim. See allopurinol
alprazolam, 167, 169, 170, 184, 189, 235, 247, 254, 264, 265, 267, 296, 297, 299, 320, 385
alprazolam-XR, 189, 190
Altace. See ramipril
amantadine, 115
Ambien. See zolpidem
amitriptyline, 34, 260, 358
d-amphetamine, 52, 54, 172
amphetamine salts. See mixed amphetamine salts
Anafranil. See clomipramine
Antabuse. See disulfiram
Aplenzin. See bupropion-XL
Aranesp. See darbepoetin alfa
aripiprazole, 16, 23, 25, 27, 37, 38, 41, 44, 48, 113, 116, 137, 142, 175, 179, 221, 271, 287, 289, 302, 303, 332, 351, 369
armodafinil, 39, 40, 94
asenapine, 38, 116, 131, 137, 175, 338
aspirin, 229
Atarax. See hydroxyzine
atenolol, 288
Ativan. See lorazepam
atomoxetine, 364, 405
atorvastatin, 34, 360
Belsomra. See suvorexant
Belviq. See lorcaserin
Benadryl. See diphenhydramine
benztropine, 126, 128, 131, 269
Boniva. See ibandronate
botulinum toxin (Botox), 29, 184
Brintellix. See vortioxetine
bupropion, 116, 156, 206, 260
bupropion-IR, 204, 205
bupropion-SR, 6, 8, 34, 37, 52, 194, 200, 296
bupropion-XL, 77, 109, 149, 150, 170, 232, 234, 236, 265, 285, 304, 363, 393
BuSpar. See buspirone
buspirone, 8, 10, 11, 14, 22, 25, 26, 27, 34, 76, 149, 175, 177, 224, 319, 405
Byetta. See exenatide
Bystolic. See nebivolol
Calan. See verapamil
Campral. See acamprosate
carbamazepine, 25, 116, 260
Catapres. See clonidine
Celexa. See citalopram
Chantix. See varenicline
chlordiazepoxide, 9, 11
chlorpromazine, 88, 116
cholestyramine, 52
chromium picolinate, 250
ciprofloxacin, 374, 377
citalopram, 52, 203, 204, 205, 231, 234, 236, 296
clomipramine, 224
clonazepam, 34, 91, 92, 95, 281, 347, 348, 373
clonidine, 323, 325, 405
clonidine-ER, 323, 325
clorazepate, 195
clozapine, 25, 29, 116, 127, 129, 141–144
Clozaril. See clozapine
Cogentin. See benztropine
Concerta. See methylphenidate
Contrave. See naltrexone/bupropion combination
cyclobenzaprine, 260
Cymbalta. See duloxetine
Cytomel. See tri-iodothyronine
darbepoetin alfa, 68
Daytrana. See methylphenidate transdermal patch
Depakote. See divalproex sodium
Deplin. See L-methylfolate
desipramine, 77, 189, 259, 261
desvenlafaxine, 26, 27, 112, 189, 224, 246, 248, 287
Desyrel. See trazodone
Dexedrine. See d-amphetamine
dextromethorphan, 259, 260
Dextrostat. See d-amphetamine
diazepam, 26, 27, 68, 355
diphenhydramine, 78, 88, 162, 352
diphenoxylate and atropine, 52
disulfiram, 393–394
divalproex sodium, 25, 84, 87, 91, 93, 116, 281, 296, 297, 298
divalproex sodium-ER, 332, 333
doxepin, 42, 68, 74, 76, 78, 117, 162, 241, 352, 353, 358
doxylamine, 352
duloxetine, 20, 23, 26, 34, 35, 37, 48, 73, 76, 106, 108, 109, 167, 169, 184, 185, 188, 189, 200, 224, 320
Duragesic. See fentanyl transdermal
Effexor-XR. See venlafaxine-XR
Elavil. See amitriptyline
eletriptan, 184
Emsam. See selegiline transdermal patch
epoetin, 68
Equetro. See carbamazepine
escitalopram, 6, 8, 10, 14, 68, 72, 153, 203, 204, 246, 248, 285, 286, 332, 333, 335, 339, 373
eszopiclone, 237, 252, 373
exenatide, 148
ezetimibe, 148
Fanapt. See iloperidone
FazaClo. See clozapine
fenfluramine, 118
fentanyl transdermal patch, 184
ferrous sulfate, 229
fexofenadine, 229
Flexeril. See cyclobenzaprine
fluoxetine, 20, 28, 30, 34, 52, 200, 203, 215, 218, 219, 224, 258, 259, 268, 271, 302, 304, 332, 399, 401
fluphenazine, 116
fluticasone–salmeterol, 34, 148
furosemide, 229
gabapentin, 25, 73, 234, 236, 241, 255, 388, 391, 394
Gabitril. See tiagabine
Geodon. See ziprasidone
glipizide, 148
Glucophage. See metformin
Glucotrol. See glipizide
guanfacine, 323, 405
guanfacine-ER, 321, 323, 325, 403, 404
Haldol. See haloperidol
haloperidol, 84, 116, 141, 269, 346, 351, 378, 379
Hetlioz. See tasimelteon
hydroxyzine, 41, 78, 184, 314, 315, 358
ibandronate, 184
ibuprofen, 107, 247
iloperidone, 116, 131, 133, 137
Inderal. See propranolol
interferon, 245, 247
Intuniv. See guanfacine-ER
Invega. See paliperidone
Kapvay. See clonidine-ER
Klonopin. See clonazepam
Lamictal. See lamotrigine
lamotrigine, 25, 48, 109, 114, 116, 206, 284, 286, 296, 299, 300
lansoprazole, 52, 373
Lasix. See furosemide
latanoprost, 148
Latuda. See lurasidone
levothyroxine, 184, 229, 373
Lexapro. See escitalopram
Librium. See chlordiazepoxide
Lipitor. See atorvastatin
lisdexamfetamine, 84, 195, 399, 402, 404
lisinopril, 229
lithium, 25, 91, 93, 113, 114, 116, 255, 369, 416
lomotil. See diphenoxylate and atropine
Lopressor. See metoprolol
Lorazepam, 68, 72, 73, 74, 76, 190, 253, 300, 303, 412, 416, 426
lorcaserin, 115, 118
loxapine, 130
Loxitane. See loxapine
Lunesta. See eszopiclone
lurasidone, 38, 116, 131, 137, 175, 221, 290, 306, 337
Lyrica. See pregabalin
Mellaril. See thioridazine
metformin, 110, 115, 117, 118, 130, 148, 361
L-methylfolate, 172, 304, 319, 373, 416
methylphenidate, 106, 194, 306, 402
methylphenidate-ER, 106, 109, 265
methylphenidate-LA, 40
methylphenidate OROS, 194
methylphenidate SODAS, 195
methylphenidate transdermal patch, 195, 399
methylphenidate-XR, 399
metoprolol, 361
Minipress. See prazosin
Mirapex. See pramipexole
mirtazapine, 16, 52, 68, 72, 76, 77, 110, 116, 170, 247, 250, 251, 252, 255, 296, 297, 299, 300, 412, 423
mixed amphetamine salts, 44, 48, 84, 332, 333
mixed amphetamine salts-XR, 40, 41
modafinil, 39, 40, 92, 94, 111, 172, 186, 187, 188, 206, 235, 236, 306, 373
Motrin. See ibuprofen
naltrexone, 394
naltrexone/bupropion combination, 115
Naprosyn. See naproxen
naproxen, 184
Nardil. See phenelzine
Navane. See thiothixene, thiothixine
nebivolol, 68
nefazodone, 16, 27
Neurontin. See gabapentin
Nexium. See omeprazole
niacin, 373
Niaspan. See niacin
Norpramin. See desipramine
norquetiapine, 77, 78–79, 175
nortriptyline, 110, 112, 148, 372, 376, 426
Nuvigil. See armodafinil
odansetron, 184
olanzapine, 38, 52, 54, 55, 116, 125, 127, 128, 137, 300, 380
olanzapine–fluoxetine combination, 290, 301
Oleptro. See trazodone-ER
omeprazole, 34, 184
orlistat, 111, 115, 118
oxazepam, 253
paliperidone, 87, 116, 130, 137, 194, 255
Pamelor. See nortriptyline
Pantoprazole. See protonix
Parnate. See tranylcypromine
paroxetine, 34, 68, 148, 156, 166, 168, 200, 224, 258, 259, 268, 281, 314, 315, 385
paroxetine-CR, 150, 314, 315
Paxil. See paroxetine
perphenazine, 129, 190, 191
phenelzine, 173
pramipexole, 39, 234, 241
Pravachol. See pravastatin
pravastatin, 148
prazosin, 156, 323
pregabalin, 25, 186, 187, 188, 241, 388, 391
Prevacid. See lansoprazole
Prilosec. See omeprazole
Pristiq. See desvenlafaxine
Procrit. See epoetin
Prolixin. See fluphenazine
propranolol, 34, 318, 323
Protonix. See pantoprazole
Provigil. See modafinil
Prozac. See fluoxetine
Q-Symia. See topiramate/phentermine combination
Questran. See cholestyramine
quetiapine, 38, 74, 76, 77–79, 80, 127, 128, 137, 153, 154, 155, 172, 175, 215, 216, 217, 290, 350, 358, 380, 412, 426
quetiapine-XR, 38, 75, 76, 78, 116, 216, 217, 218, 219, 221, 290
quinidine, 259
ramelteon, 155, 235, 236, 239, 241, 272, 352
ramipril, 148
Reclast. See zoledronic acid
Relpax. See eletriptan
Remeron. See mirtazapine
Requip. See ropinirole
ReVia. See naltrexone
Risperdal. See risperidone
risperidone, 84, 87, 111, 112, 124, 136, 141, 271, 296, 346, 347, 380, 412
Ritalin-LA. See methylphenidate-LA
ropinirole, 39, 234, 241
Rozerem. See ramelteon
Saphris. See asenapine
Sarafem. See fluoxetine
selegiline, 110, 116, 171, 195, 255
Serax. See oxazepam
Seroquel. See quetiapine
sertraline, 3, 21, 28, 30, 34, 52, 122, 149, 150, 156, 200, 202, 206, 224, 254, 265, 268, 281, 360, 362, 363, 383, 385, 403, 404, 412, 416
Serzone. See nefazodone
sibutramine, 118
Silenor. See doxepin
simvastatin, 217
Sinequan. See doxepin
sofosbuvir, 249
Sonata. See zaleplon
Sovaldi. See sofosbuvir
Stelazine. See trifluoperazine
Strattera. See atomoxetine
suvorexant, 354
Symbyax. See olanzapine–fluoxetine combination
Symmetrel. See amantadine
Synthroid. See levothyroxine
tasimelteon, 239
temazepam, 253
Tenex. See guanfacine
thioridazine, 88, 116, 133
thiothixene, 84, 87, 88, 90, 93, 128, 351
Thorazine. See chlorpromazine
tiagabine, 151, 156, 231, 233, 314, 315, 319, 322
Topamax. See topiramate
topiramate, 52, 54, 56, 115, 118, 206, 264
topiramate/phentermine combination, 115
Toprol-XL. See metoprolol
tramadol, 247
Tranxene. See clorazepate
tranylcypromine, 173
trazodone, 6, 8, 22, 34, 37, 42, 117, 128, 268, 269, 301, 303, 335, 358
trazodone-ER, 27, 116, 194, 304
trifluoperazine, 132
tri-iodothyronine, 112
Trilafon. See perphenazine
Ultram. See tramadol
Valium. See diazepam
valproic acid, 412
varenicline, 393
venlafaxine-ER, 267
venlafaxine-XR, 52, 73, 76, 172, 200, 224, 264, 271
Ventolin. See albuterol
verapamil, 217
Versacloz. See clozapine
Viibryd. See vilazodone
vilazodone, 14, 16, 22, 116, 175
Vistaril. See hydroxyzine
vitamin E, 128
vortioxetine, 15, 16, 116, 175
Vyvanse. See lisdexamfetamine
Wellbutrin. See bupropion
Xalatan. See latanoprost
Xanax. See alprazolam
Xanax-XR. See alprazolam-ER
Xenical. See orlistat
zaleplon, 76, 232, 234, 235, 237
Zestril. See lisinopril
Zetia. See ezetimibe
ziprasidone, 22, 116, 130, 133, 137, 174, 272, 306, 337, 351
Zocor. See simvastatin
Zofran. See odansetron
zoledronic acid, 68
Zoloft. See sertraline
zolpidem, 68, 76, 235, 237, 247, 250, 252, 265, 349, 385
zolpidem-CR, 255, 300, 383, 385
zolpidem-ER, 194, 267
Zonegran. See zonisamide
zonisamide, 115
Zyprexa. See olanzapine
